Ur24Technology Launches New and Unique ‘TrueClr’ External Catheter Line
Ur24Technology Inc., a privately held medical device company, has launched the TrueClr catheter product line – offering physicians, nurses and patients a choice that will eliminate catheter-associated urinary tract infections in hospitals, increase patient comfort and quality of life, and lower health care costs.
The first external catheter designed to actively empty the bladder, the new latex-free TrueClr product line for adults and children will be showcased at Medica 2022, one of the world’s leading medical trade fairs, in Dusseldorf, Germany from Nov. 13-17.
Dr. Jon Meliones, M.D., FCCM, medical director at Ur24Technology, said: “I am convinced the TrueClr external catheters will fundamentally revolutionize medical practices. It’s an active elimination system vs. passive - the only catheter of its kind in the world.” Dr. Meliones will be a featured speaker at Medica 2022.
US data shows that internal catheters are associated with 80 percent of hospital-related urinary tract infections, which cost the health care system an estimated $450 million yearly. Nearly 13,000 deaths annually are related to internal catheters. Key features of the TrueClr product line include:
- Eliminates internal catheter-associated urinary tract infections
- Uses light, continuous section
- Non-invasive, non-adhesive, comfortable
- Leak proof design
- Avoids urine contact with skin
- Eliminates skin irritation and inflammation
- Portable & reusable – in hospitals or at home, with easy cleaning
- Covered under Medicare Part B, DME reimbursement
Ur24 Technology has a strategic partnership with Miami-based DemeTECH Corp. to manufacture and distribute TrueClr products in the US and internationally, using its distribution network in 132 countries. The companies will jointly promote TrueClr, which will be co-branded, at Medica 2022.
About Ur24Technology, Inc.
Ur24Technology, Inc. is a privately held medical device company located in Southern California that was founded in 2016 by Landon Duval. Five different external catheter prototypes were researched, designed and developed – leading to the TrueClr external catheter range of products. These revolutionary products perfectly fit the company’s core mission: to improve patient care through innovation.
Learn more at www.ur24technology.com or call 1-833-448-7248.
About DemeTECH Corp.
Headquartered in Miami, Florida, DemeTECH, is a world-renowned leader in surgical sutures, mesh and bone wax. DemeTECH strives to enhance doctor-patient relationships through hard work, dedication, and a commitment to the pursuance of cutting-edge technology and innovation. DemeTECH’s N95 masks and TrueClr external catheters are made in the USA with American materials.
Learn more at https://demetech.us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005156/en/
Contact information
Victoria Suarez
Chief Operating Officer
949.629.5424
info@ur24technology.com
www.ur24technology.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission (EC) Approves Henlius and Organon’s BILDYOS ® (denosumab) and BILPREVDA ® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively19.9.2025 13:00:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL,biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919502394/en/ “The EC approvals of BILDYOS and BILPREVDA mark a pivotal moment in expanding access to essential bone care treatments for millions of Europeans, particularly women, who are disproportionately affected by osteoporosis,” said Nico Van Hoecke, Head, International Commercial at Organon.3,4 “These biosimilars may offer additional treatment options across several therapeutic areas associated with bone loss, including osteoporosis, and reflect Organon’s commitment to advancing women’s health through access to im
Cluster Reply Supports Riverty’s AI-first Strategy for Omnichannel, Human-centric Customer Service19.9.2025 12:15:00 EEST | Press release
Cluster Reply, the Reply company specialised in digital platform solutions leveraging Microsoft technologies, has partnered with fintech company Riverty to accelerate the rollout of a pioneering customer service platform – delivered in record time of just 100 days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919101836/en/ The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The platform leverages Microsoft Dynamics 365 Custom
L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 11:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering with the Media Lab’s unique research approach. Together, they intend to explore sustainable engineering solutions that redefine industries, from creating smarter
REJO MULTI Unveiled at InterTabac 2025, Featuring Dual-Heating and Cross-Brand Compatibility19.9.2025 11:00:00 EEST | Press release
REJO, a global heat-not-burn (HNB) pioneer, officially unveiled REJO MULTI device at InterTabac 2025 as one of the exhibition’s most anticipated products. The device introduces a dual-heating system that pairs AirFlow and Round Heating technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919713971/en/ REJO MULTI Product Launch Event “REJO MULTI represents a major step forward in HNB technology,” said Loic Li, the Global Sales Director of REJO. “Its open compatibility allows users to explore multiple brands and flavors with a single device, while our dual-heating system ensures even heating, enhanced aroma delivery, and consistent nicotine satisfaction.” “Our goal with REJO MULTI is to empower users with choice and flexibility, while providing retailers and partners with an innovative, market-ready product that elevates the smoking alternative experience,” said Tibor Braun, the Western Europe Manager of REJO. “This
SMBC Group and Jefferies Significantly Expand Their Global Strategic Alliance19.9.2025 11:00:00 EEST | Press release
Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc. (NYSE: SMFG) (“SMFG”), Sumitomo Mitsui Banking Corporation (“SMBC”), and SMBC Nikko Securities Inc. (“SMBC Nikko”) (collectively, “SMBC Group”) announced today that they are significantly expanding their Global Strategic Alliance. SMBC Group and Jefferies initially entered into a Strategic Alliance in 2021 to collaborate on future corporate and investment banking business opportunities. In 2023, the Alliance was expanded to enhance collaboration across M&A, equity and debt capital markets, with a particular focus on investment grade clients in the U.S. SMBC Group and Jefferies subsequently added Memoranda of Understanding to expand their alliance to the EMEA region, Canada, Asia and Australia, as well as to expand the scope of Joint Coverage initiatives to larger global sponsors, pre-IPO companies, and sub-investment grade corporate clients. Today, Jefferies and SMBC Group announce the n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom